The global sphingolipids market is witnessing substantial growth, with a valuation of approximately USD 564.0 million in 2021. According to market projections, the market is expected to surge ahead at a compound annual growth rate (CAGR) of 5.1%, reaching an estimated valuation of around USD 991.8 million by the end of 2032.
One of the primary drivers of this growth is the increasing utilization of conventional lipid-based drug delivery systems (LBDDS), which accounted for a significant 61.9% share of the global sphingolipids market in 2021. LBDDS play a crucial role in enhancing drug solubility, stability, and bioavailability, driving their adoption across various pharmaceutical applications.
Request Your Detailed Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-15713
The large family of lipids known as sphingolipids is becoming more and more prevalent in pharmaceutical formulations due to its unique properties and potential for therapeutic applications. They are necessary for the structure and signaling of cells. Sphingolipid sales are anticipated to increase as a result of the growing demand for both natural and synthetic sphingolipids and monomers in the manufacturing of various pharmaceutical products.
This element may greatly increase the uptake and consumption of sphingolipid medications. Over the course of the projection period, increasing product releases and approvals are anticipated to support market expansion as well.
Key Takeaways from Market Study:
- Sphingomyelin is the leading segment as a product and holds approximately 0% market share in 2021, due to its anti-cancer, bacteriostatic, and cholesterol-lowering characteristics.
- Synthetic sphingolipids are the leading segment by source, and held about 4% market share in 2021, owing to their potential as therapeutic prospects for treating a range of medical problems.
- Conventional lipid-based drug delivery systems (LBDDS) is the leading segment in terms of application holding about 9% of the market share, as compared to traditional tablets or powder-filled capsules, as they can improve bioavailability and reduce dissolving rate-limited absorption because of their pharmacological composition in a solubilized condition.
- Semi-solid form of sphingolipids is the leading form as of 2021, withholding about 3% of the global market share, owing to the property of reduced adverse side effects when a high drug load is applied to the area where the medication is actually required.
- Pharmaceutical companies are the leading end users of the global market as of 2021, withholding about 5% of the market share, because of increased outsourcing, innovative modalities, and creative patient outreach tactics.
- By region, North America is leading in the global sphingolipids market and is expected to continue to do so with a projected CAGR of 4% during the forecasted years.
“Rising initiatives to promote health benefits of sphingolipids products, as well as the increasing ongoing research and development in modifying novel sphingolipids formulations is set to propel the market of sphingolipids across the globe,” says an analyst of Future Market Insights.
Market Competition
Companies are actively working to increase their market share in this industry by forming strategic agreements to diversify their respective service offerings and sphingolipid production capacities.
- In January 2022, Pfizer and Acuitas Therapeutics reached an agreement on Lipid Nanoparticle Delivery System for mRNA vaccines and therapeutics.
- June 2022: To support customers’ scientific research, CD Bioparticles, enlarged its lipid system portfolio and introduced a number of Sphingolipids products. With the addition of Phosphosphingolipids, Ceramides, Sphingolipid Metabolism, Sphingosines, Glycosphingolipids, Phytosphingosine, and Sphingomyelin, researchers now have more options to choose from and employ in lipid system applications.
Key Companies Profiled
- Merck KGaA
- CordenPharma International
- Lipoid GmbH
- LARODAN AB
- Croda International Plc.
- Biosynth, Santa Cruz Biotechnology, Inc.
- Creative Enzymes
- CD Bioparticles
- Cayman Chemical Company
- Biosolve BV
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-15713
Key Segments Covered In Sphingolipids Industry Research
By Product:
- Ceramide
- Sphingomyelin
- Glucosylceramide (GlcCer)
- Lactosylceramide (LacCer)
- Ganglioside GM3
- Other
By Source:
- Synthetic
- Semi-synthetic
- Natural
By Application:
- Conventional Lipid-based Drug Delivery Systems (LBDDS)
- Self-Emulsifying Drug Delivery Systems (SEDDS)
- Self-Microemulsifying Drug Delivery Systems (SMEDDS)
- Liposomes
- Solid Lipid Nanoparticles
- Nanostructured Lipid Carriers
- Others
By Form:
- Liquid
- Semi-solid
- Solid
By End User:
- Pharmaceutical Companies
- Biopharmaceutical Companies
- Academics and Research Institutes
- Others
Get Full Market Analysis Now: Purchase The Report:
https://www.futuremarketinsights.com/checkout/15713
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
